69 results
PRER14A
BXRX
Baudax Bio, Inc.
25 Aug 23
Preliminary revised proxy
4:01pm
of cytokine release syndrome and neurotoxicity, and adverse events have resulted in the death of patients. Certain of our product candidates, such as TI-168 … from T cell therapy may be complicated and difficult to manage, which could result in patient death or other significant issues. Additionally, it can
DEFA14A
EX-99.2
BXRX
Baudax Bio, Inc.
9 Aug 23
Additional proxy soliciting materials
5:28pm
of cytokine release syndrome and neurotoxicity, and adverse events have resulted in the death of patients. Certain of our product candidates, such as TI … to manage, which could result in patient death or other significant issues. Additionally, it can be difficult to determine if the serious adverse
8-K/A
EX-99.2
BXRX
Baudax Bio, Inc.
9 Aug 23
Other Events
5:27pm
of cytokine release syndrome and neurotoxicity, and adverse events have resulted in the death of patients. Certain of our product candidates, such as TI … to manage, which could result in patient death or other significant issues. Additionally, it can be difficult to determine if the serious adverse
DEFA14A
cc85es
5 Jul 23
Additional proxy soliciting materials
5:28pm
8-K
xhuc3d0 11k
5 Jul 23
Entry into a Material Definitive Agreement
5:26pm
8-K
EX-2.1
wtaou58mdp 4in
5 Jul 23
Entry into a Material Definitive Agreement
5:26pm
8-K
jegnosgl9ozux7b4
27 Jun 23
Submission of Matters to a Vote of Security Holders
4:05pm
424B3
md1uiemwmjijiip6
28 Apr 23
Prospectus supplement
4:02pm
8-K
EX-99.1
77191 wy8rgqs6a2sd3
23 Aug 22
Regulation FD Disclosure
9:02am
8-K
brt5vw95ksanw7b1
20 May 22
Submission of Matters to a Vote of Security Holders
4:07pm
8-K
EX-99.1
z0fd7
20 Apr 22
Regulation FD Disclosure
8:34am